Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 29.01.2025
PNE AG
Company Name:
PNE AG
ISIN:
DE000A0JBPG2
Reason for the research:
Update
Recommendation:
Buy
from:
29.01.2025
Target price:
19,00 Euro
Target price on sight of:
12 Monate
Last rating change:
02.02.2023: Hochstufung von Hinzufügen auf Kaufen
Analyst:
Dr. Karsten von Blumenthal
First Berlin Equity Research hat ein Research U [ … ]
Wed, 29.01.2025
Lisata Therapeutics Inc
Company Name:
Lisata Therapeutics Inc
ISIN:
US1280583022
Reason for the research:
Update
Recommendation:
BUY
from:
29.01.2025
Target price:
USD15.00
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on Lisata Therapeutics, Inc. (ISI [ … ]
Wed, 29.01.2025
Westwing Group SE
Company Name:
Westwing Group SE
ISIN:
DE000A2N4H07
Reason for the research:
Update
Recommendation:
Buy
from:
29.01.2025
Target price:
EUR 17.00
Target price on sight of:
12 months
Last rating change:
Analyst:
Henry Wendisch
Trading update confirms guidance reach at upper end; chg. est
Topic: WEW released a FY'24 trading updat [ … ]
Mon, 27.01.2025
Eloro Resources Ltd.
Company Name:
Eloro Resources Ltd.
ISIN:
CA2899003008
Reason for the research:
Update Report
Recommendation:
Buy
from:
27.01.2025
Target price:
CAD 12.40 (previously CAD 12.70)
Target price on sight of:
24 months
Last rating change:
-
Analyst:
Peter Thilo Hasler
Eloro Resources has discovered a high-grade tin intercept in its [ … ]
Mon, 27.01.2025
UmweltBank AG
Company Name:
UmweltBank AG
ISIN:
DE0005570808
Reason for the research:
Research Comment
Recommendation:
Buy
Target price:
10.00 EUR
Target price on sight of:
31.12.2025
Last rating change:
Analyst:
Cosmin Filker, Marcel Goldmann
You can download the research here: http://www.more-ir.de/d/31671.pdf
Contact for questions:
GB [ … ]
Mon, 27.01.2025
q.beyond AG
Company Name:
q.beyond AG
ISIN:
DE0005137004
Reason for the research:
Update
Recommendation:
Buy
from:
27.01.2025
Target price:
EUR 1.10
Target price on sight of:
12 months
Last rating change:
Analyst:
Philipp Sennewald
Profitable growth ahead after transitionary FY24e
After a rather uninspiring operating performance in FY23, [ … ]
Mon, 27.01.2025
Cantourage Group SE
Company Name:
Cantourage Group SE
ISIN:
DE000A3DSV01
Reason for the research:
Update
Recommendation:
Buy
from:
27.01.2025
Target price:
EUR 12.50
Target price on sight of:
12 months
Last rating change:
Analyst:
Christian Sandherr
FY24 with explosive growth // new high(t)s in sight; PT Up
Topic: Following the regulatory changes [ … ]
Fri, 24.01.2025
Borussia Dortmund GmbH & Co KGaA
Company Name:
Borussia Dortmund GmbH & Co KGaA
ISIN:
DE0005493092
Reason for the research:
Update
Recommendation:
BUY
from:
24.01.2025
Target price:
EUR 5.50
Target price on sight of:
12 months
Last rating change:
Analyst:
Philipp Sennewald
Sahin released following 4 consecutive losses
Topic: Following Tuesday’s loss [ … ]
Tue, 21.01.2025
Lisata Therapeutics Inc
Company Name:
Lisata Therapeutics Inc
ISIN:
US1280583022
Reason for the research:
Initiation of coverage
Recommendation:
BUY
from:
21.01.2025
Target price:
USD15.00
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research on 21/01/2025 initiated coverage on Lisata Therap [ … ]
Tue, 21.01.2025
Nabaltec AG
Company Name:
Nabaltec AG
ISIN:
DE000A0KPPR7
Reason for the research:
Update
Recommendation:
Buy
from:
21.01.2025
Target price:
EUR 25.00
Target price on sight of:
12 months
Last rating change:
Analyst:
Christian Sandherr
Ending FY24 on a high note; FY25 with additional growth
Nabaltec to reach upper end of FY24e EBIT margin [ … ]
